Format

Send to:

Choose Destination
See comment in PubMed Commons below
Neuropsychiatr Dis Treat. 2009;5:547-51. Epub 2009 Nov 2.

Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide.

Author information

  • 1Section of Pediatric Neurology, Departments of Neurology and Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. stafstrom@neurology.wisc.edu

Abstract

OBJECTIVE:

This review summarizes the treatment of Lennox-Gastaut syndrome, an intractable epileptic encephalopathy of early childhood. In particular, the review focuses on rufinamide, a recently released anticonvulsant medication with reported effectiveness in this epilepsy syndrome.

METHODS:

A systematic literature search (PubMed) was performed to review the existing literature pertaining to the treatment of Lennox-Gastaut syndrome as well as studies involving rufinamide as an anticonvulsant medication.

RESULTS:

The published literature to date documents a beneficial effect of rufinamide on children over 4 years old with Lennox-Gastaut syndrome. Studies indicate a significant decrease in tonic and atonic seizure frequency as well as total seizure frequency compared to placebo-treated children. Rufinamide appears to be well tolerated and a safe medication, somnolence and vomiting being the most common side effects.

CONCLUSIONS:

Rufinamide is a promising adjunctive therapy for Lennox-Gastaut syndrome, an intractable childhood epilepsy. To ensure its optimal effectiveness, clinicians must be familiar with the medication's clinical response profile and potential for adverse effects.

KEYWORDS:

Lennox-Gastaut syndrome; epilepsy; epileptic encephalopathy; pediatric; rufinamide

PMID:
19898669
[PubMed]
PMCID:
PMC2773286
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk